Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
Introduction In patients with axial spondyloarthritis (axSpA), biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended to those with inadequate response or contraindications to non-steroidal anti-inflammatory drugs (NSAIDs). In case of failure of the first bDMARD, a switch within...
Saved in:
Main Authors: | Xenofon Baraliakos, Denis Poddubnyy, Ludwig Hammel, Marvin Heyne, Justyna Veit, Claudia Jentzsch |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-09-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/9/e039059.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
South African Rheumatism and Arthritis Association 2024 guidelines for the management of axial spondyloarthritis
by: A B Maharaj, et al.
Published: (2024-10-01) -
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
by: Sofia Ramiro, et al.
Published: (2025-01-01) -
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
by: Filip Van den Bosch, et al.
Published: (2025-02-01) -
Oxford textbook of axial spondyloarthritis
by: Vinod Ravindran
Published: (2017-01-01) -
Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis
by: Denis Poddubnyy, et al.
Published: (2025-02-01)